article Open AccessTop 1% cited

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Journal of the American Academy of Dermatology · 2017 · Vol. 76(3) · pp. 405–417

Andrew Blauvelt✉(Oregon Medical Research Center)Kim Papp(Probity Medical Research)C.E.M. Griffiths(Manchester Academic Health Science Centre)B. Randazzo(Janssen (United States))Yasmine Wasfi(Janssen (United States))Yaung‐Kaung Shen(Janssen (United States))Shu Li(Janssen (United States))Alexa B. Kimball(Beth Israel Deaconess Medical Center)

View via DOI Publisher page

Abstract

Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year.

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Asthma and respiratory diseasesMedicinePsoriasisAdalimumabPsoriasis Area and Severity IndexDermatology Life Quality IndexInternal medicinePlaceboAdverse effectSurgeryGastroenterology

MeSH terms

AdalimumabAdultAntibodies, MonoclonalDermatologic AgentsDouble-Blind MethodFemaleHumansMaleMiddle AgedPlacebosPsoriasisQuality of LifeSeverity of Illness IndexInterleukin-23Antibodies, Monoclonal, Humanized

Citations

841

FWCI

41.36

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Clinical profile and severity of nail involvement in psoriasis